Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury

NCT03296761 is registered in ClinicalTrials.gov with Jingyuan,Xu as lead sponsor.

NCT NCT03296761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03296761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury
Lead sponsor
Jingyuan,Xu
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2017
Completion date
February 20, 2018
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

evaluate the correlation between the level of esm-1 and the prognosis of the patients with ards